Pharmacoeconomic review report: Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)
Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once dail...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, December 2017
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references